Ray Gerald L & Associates LTD Boosted Its Acadia Pharmaceuticals (ACAD) Position; Ofg Bancorp (OFG) Shorts Up By 0.56%

September 17, 2017 - By Stephen Andrade

Ray Gerald L & Associates Ltd increased Acadia Pharmaceuticals Inc (ACAD) stake by 9.07% reported in 2016Q4 SEC filing. Ray Gerald L & Associates Ltd acquired 14,990 shares as Acadia Pharmaceuticals Inc (ACAD)’s stock declined 29.10%. The Ray Gerald L & Associates Ltd holds 180,280 shares with $5.20M value, up from 165,290 last quarter. Acadia Pharmaceuticals Inc now has $4.51 billion valuation. The stock increased 1.32% or $0.48 on September 15, reaching $36.83. About 2.35 million shares traded or 45.96% up from the average. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since September 17, 2016 and is downtrending. It has underperformed by 31.89% the S&P500.

Ofg Bancorp (NYSE:OFG) had an increase of 0.56% in short interest. OFG’s SI was 3.34 million shares in September as released by FINRA. Its up 0.56% from 3.32M shares previously. With 145,500 avg volume, 23 days are for Ofg Bancorp (NYSE:OFG)’s short sellers to cover OFG’s short positions. The SI to Ofg Bancorp’s float is 7.68%. The stock increased 0.52% or $0.05 on September 15, reaching $9.6. About 615,753 shares traded or 208.90% up from the average. OFG Bancorp (NYSE:OFG) has risen 14.47% since September 17, 2016 and is uptrending. It has underperformed by 2.23% the S&P500.

Among 11 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. ACADIA Pharmaceuticals had 23 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Piper Jaffray to “Overweight” on Friday, August 7. The rating was downgraded by Leerink Swann on Tuesday, May 3 to “Market Perform”. Jefferies maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Monday, September 4 with “Buy” rating. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. The rating was upgraded by Bank of America on Tuesday, November 8 to “Buy”. The firm earned “Buy” rating on Thursday, July 27 by Jefferies. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. The firm has “Neutral” rating by Goldman Sachs given on Friday, November 11. Cowen & Co maintained it with “Outperform” rating and $50 target in Sunday, August 9 report. On Friday, January 22 the stock rating was upgraded by Piper Jaffray to “Overweight”.

Investors sentiment decreased to 1.05 in 2016 Q4. Its down 0.06, from 1.11 in 2016Q3. It worsened, as 42 investors sold ACAD shares while 58 reduced holdings. 31 funds opened positions while 75 raised stakes. 119.51 million shares or 2.68% more from 116.39 million shares in 2016Q3 were reported. Canada Pension Plan Board holds 0.05% or 462,200 shares in its portfolio. The Ohio-based Victory Cap Mgmt has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Harvey Inc accumulated 251,825 shares or 3.38% of the stock. Guggenheim Limited Com stated it has 135,350 shares or 0.01% of all its holdings. Mark Sheptoff Planning Ltd Com owns 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 500 shares. Citadel Advisors Limited Liability Company accumulated 471,952 shares. Moreover, Emory University has 2.16% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). The New York-based D E Shaw Com Inc has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Qvt Limited Partnership has invested 0.21% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Bessemer Gru accumulated 117 shares or 0% of the stock. 72,550 are held by Garrison Bradford And. Barclays Public Ltd invested 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Northwestern Mutual Wealth Mngmt, Wisconsin-based fund reported 149 shares. Acuta Capital Partners Ltd Liability Company has 300,000 shares. Moreover, Tower Limited (Trc) has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

OFG Bancorp is a financial holding company. The company has market cap of $421.90 million. The Firm is engaged in providing banking and financial services through its subsidiaries. It has a 8.99 P/E ratio. The Firm operates through three divisions: Banking, Wealth Management and Treasury.

Since March 20, 2017, it had 0 insider purchases, and 3 sales for $226,336 activity. Pena Radames sold $141,966 worth of OFG Bancorp (NYSE:OFG) on Thursday, May 11.